NCI-H3122人肺癌细胞(STR鉴定正确)

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1371

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameNCI-H3122
SynonymsH3122; H-3122; NCIH3122
AccessionBTCC-1371
Resource Identification InitiativeTo cite this cell line use: NCI-H3122 (BTCC-1371)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Doubling time: 48.5 hours (PubMed=29681454).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Sequence variations
  • Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=18594010; DepMap).
Genome ancestrySource: PubMed=30894373

Origin% genome


African0
Native American0
East Asian, North1.36
East Asian, South0
South Asian1.48
European, North65.9
European, South31.26
DiseaseLung adenocarcinoma (NCIt: C3512)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:


CVCL_4Y37 (NCI-H3122-CHR-A1)CVCL_AY53 (NCI-H3122-CR1)
Sex of cellMale
Age at samplingAge unspecified
CategoryCancer cell line
STR profileSource(s): CLS; Cosmic-CLP; PubMed=20679594

Markers:
AmelogeninX
CSF1PO11,12
D5S81811,12
D7S8208,12
D8S117913,15
D13S31710,12
D16S53911,12
D18S5113,16
FGA18,21
Penta D10,13
Penta E12
TH017,9.3
TPOX10
vWA16

Run an STR similarity search on this cell line
Publications

PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)

PubMed=12759538; DOI=10.1159/000070299
Fujishita T., Loda M., Turner R.E., Gentler M., Kashii T., Breathnach O.S., Johnson B.E.
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel.
Oncology 64:399-406(2003)

PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168
Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Clin. Cancer Res. 14:4275-4283(2008)

PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)

PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0
Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L., Chung D.H., Heo D.S.
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
J. Thorac. Oncol. 8:415-422(2013)

PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846
Friboulet L., Li N.-X., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X.-Y., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov. 4:662-673(2014)

PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003
Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C., Daub H.
Comparative proteome analysis across non-small cell lung cancer cell lines.
J. Proteomics 130:1-10(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., Deberardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31803961; DOI=10.1002/jcb.29564
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resourcesCell_Model_Passport; SIDM00137
Cosmic-CLP; 1240190
DepMap; ACH-000337
IGRhCellID; H3122GEO
LINCS_LDP; LCL-1675
Biological sample resourcesBioSample; SAMN10989614
Cell line collections (Providers)CLS; 300484
NCI-DTP; NCI-H3122
Chemistry resourcesChEMBL-Cells; CHEMBL4295436
ChEMBL-Targets; CHEMBL4296475
GDSC; 1240190
PharmacoDB; NCIH3122_1104_2019
PubChem_Cell_line; CVCL_5160
Encyclopedic resourcesWikidata; Q54908028

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部